GAG
IRWD icon

Goodman Advisory Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Goodman Advisory Group’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,500
Closed -$36.8K – 170
2023
Q1 		$36.8K Buy
+3,500
New +$39.2K 0.02% 84

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Goodman Advisory Group's IRWD Position: Q2 2023 in Review

Goodman Advisory Group sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2023, closing a stake of 3,500 shares — an estimated $36.8K sold.

Goodman Advisory Group first reported a position in IRWD in Q1 2023 and held it in 1 quarter. The position peaked at $36.8K in Q1 2023. 252 funds tracked by Wall St. Rank hold IRWD as of Q2 2023.

  • Goodman Advisory Group reported no remaining Ironwood Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Goodman Advisory Group sold 3,500 Ironwood Pharmaceuticals shares in Q2 2023, an estimated $36.8K.
  • Goodman Advisory Group first reported a position in Ironwood Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Goodman Advisory Group's Ironwood Pharmaceuticals position peaked at $36.8K in Q1 2023.
  • 252 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2023.

Based on Goodman Advisory Group's 13F filing for Q2 2023, filed 11 Aug 2023.